Notable Results with Dual Hormonal Therapy Using Fulvestrant and Anastrozole in Metastatic Breast Cancer

Metastatic hormone receptor-positive breast cancer is considered incurable (unable to achieve a complete cure). Some patients, with anastrozole , a third-generation aromatase inhibitor, receive estrogen-suppressing treatment that controls the disease for years, but median survival is 41.3 months. Small clinical trials showed that adding the selective estrogen receptor-suppressing drug fulvestrant (Faslodex) to anastrozole would be more effective, leading to the planning of S0226 , this phase-3 clinical trial. Progression-free survival results from S0226 had previously been reported: median progression-free survival was 15 months with fulvestrant plus anastrozole and 13.5 months with anastrozole alone. Updated long-term results after a median follow-up of 7 years were presented on 28 March 2019 in NEJM.
Study Details
Patients were randomly assigned to two groups: the control group received anastrozole alone, while the experimental group received fulvestrant plus anastrozole. For subgroup analysis, patients were also stratified according to previous adjuvant (protective) tamoxifen use.
- Of the 707 patients enrolled, 694 had data suitable for analysis.
- In the fulvestrant plus anastrozole (combination) group, among 349 women there were 247 deaths (% 71), and in the monotherapy group, among 345 women there were 261 deaths (% 76).
- Median overall survival was 49.8 months in the combination group and 42 months in the monotherapy arm.
- For the entire patient group, adding fulvestrant to anastrozole reduced the risk of death by %18.
- In subgroup analysis: - Among women who had not previously received tamoxifen, median overall survival was longer with combination therapy than with anastrozole alone (52.2 months and 40.3 months, respectively). - Among women who had previously received tamoxifen, overall survival was similar in the two groups (median, 48.2 months and 43.5 months).
- In both groups, the frequency of serious (grade 3 to 5) adverse effects was similar.
- Approximately %45 of patients in the anastrozole group were subsequently allowed to receive fulvestrant (called “cross-over” in clinical trial terminology).
In conclusion, adding fulvestrant to anastrozole was associated with a significant increase in long-term survival compared with anastrozole alone, even though a substantial proportion of patients receiving anastrozole later switched to fulvestrant. The results suggest that the benefit is particularly pronounced in patients who have not previously received hormone-suppressing treatment. These results may lead to FDA approval of fulvestrant in combination with anastrozole for metastatic hormone receptor-positive breast cancer in the coming period.
Sources
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
NEJM, 28 March 2019.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.